Medical condition
Melanoma
Melanoma is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- lifileucel (AMTAGVI) Antineoplastic and immunomodulating agents (L01)
- binimetinib (MEKTOVI) Antineoplastic and immunomodulating agents (L01)
- ipilimumab (YERVOY) Antineoplastic and immunomodulating agents (L01)
- encorafenib (BRAFTOVI) Antineoplastic and immunomodulating agents (L01)
- pembrolizumab (KEYTRUDA) Antineoplastic and immunomodulating agents (L01)
- nivolumab (OPDIVO) Antineoplastic and immunomodulating agents (L01)
- trametinib (MEKINIST) Antineoplastic and immunomodulating agents (L01)
- vemurafenib (ZELBORAF) Antineoplastic and immunomodulating agents (L01)
- dabrafenib (TAFINLAR) Antineoplastic and immunomodulating agents (L01)
- tilmanocept (LYMPHOSEEK) Various (V09)
- anti-melanoma mab fragments (TECNEMAB K1) Various (V09)
- tebentafusp (KIMMTRAK) Antineoplastic and immunomodulating agents (L01)
Latest Melanoma news
Personalized mRNA Cancer Vaccines: A New Era for Melanoma Treatment
Personalized mRNA cancer vaccines are emerging as a powerful new weapon against melanoma, leveraging individual patient tumor data to create tailored treatments. This innovative approach, building on the success of mRNA technology, shows significant promise in preventing cancer recurrence and offers new hope for patients.
Regeneron Immunotherapy Combo Fails in Melanoma Trial
Regeneron's recent melanoma trial results raise questions about the future of its immunotherapy combo. Analysts must assess the competitive landscape and investment implications.
FDA Blocks Melanoma Drug Amid Confusion Under Makary Leadership
The FDA has blocked a new melanoma drug, leading to confusion under the leadership of Dr. Makary. This decision has significant implications for the pharmaceutical landscape.
COFEPRIS Approval Pathway: Insights on Novel Immunotherapies for Advanced Melanoma
This article delves into the COFEPRIS approval process for innovative immunotherapies targeting advanced melanoma, highlighting key insights and drug developments.
FDA Approval OncoBlast: Market Impact for Advanced Melanoma
This article analyzes the FDA approval of OncoBlast for advanced melanoma, highlighting its market impact and benefits for patients and healthcare providers.
AACR 2026: Pembrolizumab Bowel Cancer Success, Moderna Melanoma Data
Key updates from AACR 2026 include pembrolizumab (Keytruda) showing zero relapses in bowel cancer, Moderna's melanoma data, and Revolution Medicines' pancreatic cancer results.
Obsidian Therapeutics OBX-115 Phase 2 Melanoma Data to Be Presented at ASCO 2026
Obsidian Therapeutics will present Phase 2 clinical trial results for OBX-115, an autologous TIL cell therapy for advanced melanoma at ASCO 2026.
FDA Approval of Viruxa: Market Analysis and Clinical Review for Advanced Melanoma
This article delves into the FDA's recent approval of Viruxa for advanced melanoma, offering a comprehensive market analysis and clinical review.